Latest Administration News

Asian Battery Metals has exercised its option to acquire the Maikhan Uul Copper-Gold Project in southwestern Mongolia, adding a strategically significant asset to its portfolio with confirmed high-grade mineralisation and a long-term mining licence.

TasFoods Limited has appointed KPMG as voluntary administrators following the unsuccessful sale of its Nichols Poultry business, signalling a critical restructuring phase. A creditors' meeting is scheduled for 23 March 2026 as the company seeks new capital or buyers.

Acrux Limited has secured a $0.55 million advance on its FY26 R&D Tax Incentive, providing crucial funding to accelerate development of its Hormone Replacement Therapy following FDA regulatory confirmation.

Imugene Limited has launched a $20 million capital raising through a $12 million institutional placement and an $8 million Share Purchase Plan, alongside a convertible notes amendment to support its clinical development pipeline.

WA Kaolin Limited has responded to ASX queries clarifying that its Q2 FY2026 order book was a demand snapshot, not a sales forecast, and confirmed timely disclosure of a production shortfall linked to plant issues. The company also addressed regulatory notices, affirming no material impact on operations or securities value.

Argo Global Listed Infrastructure Limited has announced a fully franked dividend of AUD 0.045 per share for the half-year ending December 2025, alongside updated Dividend Reinvestment and Substitution Share Plan prices.

Lendlease Group has updated its dividend announcement, confirming the Dividend Reinvestment Plan price and detailing dividend amounts in Australian, New Zealand, and British currencies.

Tetratherix Limited has raised approximately $5 million to fast-track its Tutelix prostate spacer into pivotal clinical trials across Australia and the US, aiming to improve radiation therapy for prostate cancer patients.

DPM Metals has lodged a detailed technical report updating the Mineral Resource and Reserve estimates for its Chelopech mine in Bulgaria, underpinning its strategic growth plans.

Clarity Pharmaceuticals has completed enrolment in its Phase III AMPLIFY trial for the Cu-SAR-bisPSMA imaging agent, advancing its bid for FDA approval in prostate cancer diagnostics.

Telix Pharmaceuticals has announced that Part 1 of its ProstACT Phase 3 trial for TLX591-Tx met its primary safety and dosimetry objectives, with no new safety concerns. The study’s success supports ongoing global enrolment in Part 2 and regulatory engagement in the US.

Suncorp Group Limited has updated the dividend reinvestment price for its fully franked ordinary dividend relating to the six months ending December 2025. The dividend of 17 cents per share will be paid on 31 March 2026, with flexible currency options for shareholders.